To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA
(N2) non–smallcell lung cancer. Our previous phase II study had shown the efficacy of …

Accurate staging and restaging of primary tumour and mediastinal nodes in patients with
lung cancer is of significant importance. For primary tumours, computed tomography (CT) …

This prospective, randomized, phase III trial shows that prophylactic cranial irradiation
prolongs disease-free survival, decreases the rate of cerebral metastases and does not …

Background Outcome of consecutive patients with locally advanced non-small cell lung
cancer and histopathologically proven mediastional lymph node metastases treated with …

Background The efficacy of induction treatment plus surgery for improving postoperative
survival in patients with non-small-cell lung cancer (NSCLC) in stages IIIA-N2 is …

Objective The incidence of brain metastases greatly varies in patients with non-small-cell
lung cancer, and molecular markers are considered to predict brain metastases. Therefore …

Brain metastasis is a major complication of non‑small cell lung cancer (NSCLC) and leads to
most of the mortality of this disease. However, the biological mechanisms and molecular …

OBJECTIVES Multimodal management of N2 non-small-cell lung cancer is still a matter of
debate. In particular, the place of surgery for persistent N2 after induction treatment is …

Locally advanced non-small cell lung cancer (NSCLC) consists of a heterogeneous group of
patients, and the optimal treatment is still controversial. The current standard of care is …